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Aims Clinical practice guidelines restrict rhythm control therapy to patients with symptomatic atrial fibrillation (AF). The





This prespecified EAST-AFNET 4 analysis compared the effect of early rhythm control therapy in asymptomatic
patients (EHRA score I) to symptomatic patients. Primary outcome was a composite of death from cardiovascular
causes, stroke, or hospitalization with worsening of heart failure or acute coronary syndrome, analyzed in a time-
to-event analysis. At baseline, 801/2633 (30.4%) patients were asymptomatic [mean age 71.3 years, 37.5% women,
mean CHA2DS2-VASc score 3.4, 169/801 (21.1%) heart failure]. Asymptomatic patients randomized to early
rhythm control (395/801) received similar rhythm control therapies compared to symptomatic patients [e.g. AF ab-
lation at 24 months: 75/395 (19.0%) in asymptomatic; 176/910 (19.3%) symptomatic patients, P = 0.672].
Anticoagulation and treatment of concomitant cardiovascular conditions was not different between symptomatic
and asymptomatic patients. The primary outcome occurred in 79/395 asymptomatic patients randomized to early
rhythm control and in 97/406 patients randomized to usual care (hazard ratio 0.76, 95% confidence interval [0.6;
1.03]), almost identical to symptomatic patients. At 24 months follow-up, change in symptom status was not differ-
ent between randomized groups (P = 0.19).
...................................................................................................................................................................................................
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Conclusion The clinical benefit of early, systematic rhythm control was not different between asymptomatic and symptomatic
patients in EAST-AFNET 4. These results call for a shared decision discussing the benefits of rhythm control ther-
apy in all patients with recently diagnosed AF and concomitant cardiovascular conditions (EAST-AFNET 4;
ISRCTN04708680; NCT01288352; EudraCT2010-021258-20).
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Introduction
Atrial fibrillation (AF) remains a major cause of cardiovascular death,
stroke, and heart failure even on optimal current management.1
Approximately 1/3 of unselected patients with AF do not have AF-
related symptoms, more often older populations and with persistent
forms of AF.2,3 Asymptomatic AF is associated with similar rates of
stroke, cardiovascular death, and other cardiovascular events com-
pared to symptomatic AF.4–7 Some data suggest that the mortality of
asymptomatic patients may even be higher than in symptomatic
patients,4 underscoring the need to better identify and manage
asymptomatic patients with AF.
Contemporary AF guidelines recommend anticoagulation and
therapy of concomitant cardiovascular conditions in all patients with
AF, while rhythm control is restricted to symptomatic patients.1
However, the EAST-AFNET 4 trial and the earlier ATHENA trial sug-
gest that rhythm control therapy could further reduce cardiovascular
events, reporting fewer cardiovascular complications in patients
randomized to early rhythm control therapy (EAST-AFNET 4)8 or to
dronedarone (ATHENA).9 Whether the clinical benefit of
Graphical Abstract
Similar reducon of cardiovascular death, stroke, or hospitalisaon for heart failure or
acute coronary syndrome in symptomac and asymptomac paents
Our findings support the systemac, early iniaon of rhythm control therapy 
in asymptomac paents with atrial fibrillaon and concomitant 
cardiovascular condions. 
Early Rhythm Control in all paents
(n=1305/2633)
Usual Care, including symptom-directed
rhythm control therapy (n=1328/2633)
No difference in treatment paern between asymptomac and symptomac paents.
Excellent symptom control in both randomized groups at two years.
Ca. 1/4 treated with AF ablaon and 
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systematic, early rhythm control therapy is present in asymptomatic
patients with AF remains to be tested.
Methods
The current analysis was prespecified in the statistical analysis plan and
performed on the final, locked database of the EAST-AFNET 4 trial.
Design and topline results of the main trial have been published.8,10 In
brief, the EAST-AFNET 4 trial is an international, investigator-initiated,
parallel-group, open, blinded- outcome-assessment (PROBE) trial, which
randomly assigned patients who had AF diagnosed <_1 year before enrol-
ment and cardiovascular conditions to receive either early rhythm con-
trol in all patients or usual care. Early rhythm control included treatment
with antiarrhythmic drugs or AF ablation in all patients directly after ran-
domization. Usual care included rhythm control therapy to improve AF-
related symptoms.8,10
The current analyses included treatments at discharge from the ran-
domization visit, at one year and at two years of follow-up. Patients were
categorized into asymptomatic and symptomatic patients by EHRA score
at baseline (asymptomatic = EHRA I; symptomatic = EHRA II–IV). To fur-
ther explore relations between symptoms and outcomes, patients were
classified as asymptomatic (EHRA I), mildly symptomatic (EHRA II), or se-
verely symptomatic (EHRA III or EHRA IV). Patients with missing baseline
EHRA scores were excluded.
The effects of early rhythm control therapy were compared between
randomized groups (ITT analysis) in patients with different EHRA classes
and between asymptomatic and symptomatic patients at baseline. Effects
on the primary outcome (composite of death from cardiovascular causes,
stroke, or hospitalization with worsening of heart failure or acute coron-
ary syndrome, analyzed in a time-to-event analysis) as well as the second
primary outcome (number of nights spent in hospital per year) and key
secondary outcomes (rhythm, change in symptoms, left ventricular func-
tion, quality of life) were analyzed.
Data are presented as mean and standard deviation or number and
percentage. To compare data, P-values resulting from mixed linear re-
gression models for metric variables and mixed (ordinal) logistic regres-
sion models for categorical variables were used where appropriate. Sites
were modelled as random effect. For categorical variables with more
than two categories (not ordinal), a random effect was not included.
Subgroup analyses were conducted with interaction terms.
For the primary outcome and its individual components, we used Cox
regression models with an interaction term of treatment group and AF
symptom status as well as site as a shared frailty term. The treatment
effects are expressed as hazard ratios with 95% confidence interval.
The second primary outcome was analyzed with a mixed negative bi-
nomial model with treatment group and AF symptom status as inter-
action term, the log of follow-up time as offset and site as a random
effect. The treatment effect is presented as the incidence rate ratio and
95% confidence interval. The key secondary outcomes at 2 years were
analyzed after multiple imputation of missing values in survivors. The
multiple-imputation procedure was conducted with 60 imputations for a
set of continuous outcomes and covariates for adjustment based on sug-
gestions by White, Royston, and Wood (see statistical analysis plan in the
supplement of EAST-AFNET 4).8 We then calculated a mixed linear
model with the corresponding baseline measurement as covariate, a
treatment group/AF symptom interaction term and site as a random ef-
fect. The treatment effect is expressed as the adjusted mean difference
with 95% confidence interval. Data were analyzed using Stata software
(StataCorp), version 16.1, and R software, version 4.0.5 (R Project for
Statistical Computing).
Results
The study group consisted of 2633 patients randomized across 135
sites in 11 European countries between 28 July 2011 and 30
December 2016. Patients with missing baseline symptom status (156,
2.8%) were not analyzed (Figure 1). At baseline, 801/2633 (30.4%)
patients were asymptomatic (EHRA score I, mean age 71.3 years,
37.5% women, mean CHA2DS2-VASc score 3.4), whereas 1832/
2633 (69.6%) patients were symptomatic (Table 1 and Supplementary
material online, Tables S1 and S2). The majority of symptomatic
patients presented with mild or moderate symptoms (EHRA II, n =
1358, Table 1). The mean CHA2DS2-VASc score was not different
between symptomatic and asymptomatic patients. However, asymp-
tomatic patients were older, less often women, had less heart failure
but had higher rates of prior stroke or transient ischaemic attack
compared to symptomatic patients (Table 1). AF patterns and prior
rhythm control therapy also differed. Asymptomatic patients were
more often enrolled at their first episode of AF and were less likely
to be in paroxysmal AF (Table 1). Asymptomatic patients had fewer
rhythm control therapy attempts prior to enrolment using antiar-
rhythmic drugs or electrical or pharmacological cardioversion.
Baseline characteristics of asymptomatic patients were well balanced
between randomized groups (Table 1).
Anticoagulation and treatment of
concomitant cardiovascular conditions
Most asymptomatic patients received guideline-adherent oral antico-
agulation, comparable to the care in the symptomatic group at base-
line [baseline: asymptomatic 723/801 (90.3%), symptomatic 1655/
1832 (90.3%)] and during follow-up (Supplementary material online,
Table S2). Similar to symptomatic patients, treatment of concomitant
cardiovascular conditions was well balanced between groups with
the exception of slightly lower use of beta-blockers and digitalis gly-
cosides and higher use of statins in asymptomatic patients (Table 1
and Supplementary material online, Table S2, P = 0.004, P = 0.001, and
P < 0.001, respectively).
Delivery of early rhythm control and
usual care in asymptomatic patients
Of 801 asymptomatic patients, 395 were assigned to early rhythm
control and 406 to usual care (Figure 1). Rhythm control therapy was
initiated in nearly all asymptomatic patients [378/395 (95.7%)]
randomized to early rhythm control without difference to symptom-
atic patients [865/910 (95.1%)] and without effect of symptom status.
At the two year follow-up, 242/395 (59.3%) asymptomatic patients
were still receiving rhythm control therapy, compared to 601/910
(64.8%) symptomatic patients (Figure 1 and Table 2). Asymptomatic
patients randomized to early rhythm control (395/801) received
similar rhythm control therapies compared to symptomatic patients.
A total of 75/395 (19.0%) asymptomatic patients received AF ablation
within 24 months after randomization compared to 176/910 (19.3%)
symptomatic patients (P = 0.672, Table 2). This corresponds to 25%
of patients still in follow-up at two years.
Treatment patterns in patients randomized to usual care did not
differ between symptomatic and asymptomatic patients. Rate control
therapy without rhythm control therapy was given to 390 (96.1%)





































.asymptomatic patients randomized to usual care and to 884/922
(95.9%) symptomatic patients. At 2 years, 360/406 patients
(89.3%) randomized to usual care were still not receiving rhythm-
control therapy, slightly more than in symptomatic patients
randomized to usual care [781/922 (85.9%), P = 0.0487, Figure 1
and Table 2].
Primary outcome is not different based
on symptoms
Death from cardiovascular causes, stroke, or hospitalization with
worsening of heart failure or acute coronary syndrome (first primary
outcome of the trial) occurred in 79/395 asymptomatic patients
randomized to early rhythm control, and in 97/406 asymptomatic
patients randomized to usual care, with a hazard ratio of 0.76, 95% CI
[0.57; 1.03], almost identical to the overall population and to symp-
tomatic patients (P = 0.848, Figure 2 and Table 3) and to the outcome
in patients with mild to moderate or severe symptoms (Figure 2 and
Table 3). The effects of early rhythm control on individual compo-
nents of the first primary outcome were comparable for
asymptomatic, mildly or moderately symptomatic, and severely
symptomatic patients, in line with the overall population (Table 3).
There was no interaction between symptom status and treatment ef-
fect in the primary outcome or any of its components.
Safety outcomes for asymptomatic patients were similar to symp-
tomatic patients with no significant difference between groups (Table
4). Mortality and stroke were similar in the two treatment groups.
Serious adverse events related to rhythm-control therapy were rare,
more common in the group assigned to early rhythm control, and
not affected by symptom status.
Effect of early rhythm control therapy on
nights spent in hospital and on secondary
outcomes in asymptomatic and
symptomatic patients
There was no difference in nights spent in hospital per year be-
tween asymptomatic, mildly or moderately symptomatic, and se-
verely symptomatic patients (Table 3). Furthermore, nights spent
in hospital per year were not different between asymptomatic
Figure 1 Consort flow chart of the patients included in this analysis showing screening, randomization, treatment, and follow-up. Of all
patients included into the EAST-AFNET 4 trial, 21 of the 2810 patients did not meet the inclusion criteria of early atrial fibrillation (diagnosed <_1
year before enrolment) and cardiovascular conditions. After exclusion of 156 patients with missing baseline symptom status, 2633 patients were
included into the analysis with randomization to early rhythm control (n = 1305) or usual care (n = 1328). Most of the patients assigned to early
rhythm-control were initially treated with antiarrhythmic drugs, regardless of symptom status. After 2 years of follow-up, 242 of the 395 asymp-
tomatic patients (59.3%) and 601 of the 910 symptomatic patients (64.8%) who had been randomly assigned to early rhythm control therapy
were still receiving active rhythm-control therapy [atrial fibrillation ablation in 75/395 (19.0%) asymptomatic patients and in 176/910 (19.3%)
symptomatic patients; P = 0.672] randomized to early rhythm control. This corresponds to ca 25% of patients randomized to early rhythm con-
trol and still in follow-up at 24 months.













..patients randomized to early rhythm control (5.5 ± 17.9) com-
pared to asymptomatic patients randomized to usual care
(6.1 ± 19.2). At 24 months, 255/323 (78.9%) asymptomatic
patients in early rhythm control group were in sinus rhythm
compared to 170/325 (52.3%) patients in usual care (P < 0.001),
similar to the results of symptomatic patients (Table 3). There was
no interaction between symptom status and treatment effect in
any of the secondary outcomes (Table 3).
...........................................................................................
....................................................................................................................................................................................................................
Table 1 Demographic and clinical characteristics of the patients at baseline
Characteristics Overall,
N 5 2633a











Age 71 (66.0, 76) 72 (67.0, 77) 71 (65.2, 75) 72 (65.0, 76) 0.003
Female sex 1223/2633 (46%) 300/801 (37%) 629/1358 (46%) 294/474 (62%) <0.001
Body mass index (calculated) (kg/m2) 28.6 (25.5, 32.1) 28.4 (25.6, 32.0) 28.3 (25.4, 31.8) 29.4 (25.8, 33.1) 0.047
AF type <0.001
First episode 1029/2633 (39%) 390/801 (49%) 442/1358 (33%) 197/474 (42%)
Paroxysmal 901/2633 (34%) 201/801 (25%) 532/1358 (39%) 168/474 (35%)
Persistent or long-standing persistent 703/2633 (27%) 210/801 (26%) 384/1358 (28%) 109/474 (23%)
Sinus rhythm at baseline 1424/2632 (54%) 401/800 (50%) 742/1358 (55%) 281/474 (59%) 0.079
Median days since AF diagnosis (IQR) 35.0 (6.0, 110.0) 23.0 (4.0, 86.0) 44.0 (8.0, 124.8) 24.0 (4.0, 103.8) 0.002
Previous pharmacological or electrical cardioversion 1046/2602 (40%) 276/788 (35%) 564/1346 (42%) 206/468 (44%) <0.001
Concomitant cardiovascular conditions
Previous stroke or transient ischaemic attack 303/2633 (12%) 116/801 (14%) 140/1358 (10%) 47/474 (9.9%) 0.014
At least mild cognitive impairment 1110/2524 (44%) 383/777 (49%) 514/1309 (39%) 213/438 (49%) 0.007
MoCA score <0.001
None 1414/2524 (56%) 394/777 (51%) 795/1309 (61%) 225/438 (51%)
Mild 1016/2524 (40%) 343/777 (44%) 482/1309 (37%) 191/438 (44%)
Moderate 86/2524 (3.4%) 38/777 (4.9%) 29/1309 (2.2%) 19/438 (4.3%)
Severe 8/2524 (0.3%) 2/777 (0.3%) 3/1309 (0.2%) 3/438 (0.7%)
Arterial hypertension 2306/2633 (88%) 693/801 (87%) 1194/1358 (88%) 419/474 (88%) 0.64
Systolic blood pressure (mmHg) 135 (123.0, 150) 137 (123.0, 150) 135 (123.0, 149) 137 (122.0, 150) 0.23
Diastolic blood pressure (mmHg) 80 (73.0, 90) 80 (72.0, 90) 80 (74.0, 90) 80 (70.0, 89) 0.023
Stable heart failure 738/2633 (28%) 169/801 (21%) 396/1358 (29%) 173/474 (36%) <0.001
CHA2DS2-Vasc score 3.0 (2.0, 4.0) 3.0 (2.0, 4.0) 3.0 (2.0, 4.0) 3.0 (3.0, 4.0) <0.001
Chronic kidney disease of MDRD stage 3 or 4 337/2633 (13%) 104/801 (13%) 171/1358 (13%) 62/474 (13%) 0.72
Medication at discharge
Oral anticoagulation with NOAC or VKA 2378/2633 (90%) 723/801 (90%) 1223/1358 (90%) 432/474 (91%) 0.11
Digoxin or digitoxin 129/2633 (4.9%) 24/801 (3.0%) 77/1358 (5.7%) 28/474 (5.9%) 0.003
Beta-blockers 2130/2633 (81%) 624/801 (78%) 1099/1358 (81%) 407/474 (86%) 0.005
ACE inhibitors or angiotensin II receptor blocker 1838/2633 (70%) 580/801 (72%) 929/1358 (68%) 329/474 (69%) 0.41
Mineralocorticoid receptor antagonist 170/2633 (6.5%) 53/801 (6.6%) 88/1358 (6.5%) 29/474 (6.1%) 0.74
Diuretic 1067/2633 (41%) 322/801 (40%) 521/1358 (38%) 224/474 (47%) 0.004
Statin 1139/2633 (43%) 399/801 (50%) 556/1358 (41%) 184/474 (39%) 0.002
Platelet inhibitor 437/2633 (17%) 146/801 (18%) 210/1358 (15%) 81/474 (17%) 0.24
Planned therapy for rhythm control at baseline 0.15
AAD 1193/2633 (45%) 369/801 (46%) 595/1358 (44%) 229/474 (48%)
Ablation 104/2633 (3.9%) 25/801 (3.1%) 55/1358 (4.1%) 24/474 (5.1%)
None 1336/2633 (51%) 407/801 (51%) 708/1358 (52%) 221/474 (47%)
MoCA score categories: none: >_26; mild: 18–25; moderate: 10–17; severe: <10.
AF, atrial fibrillation.
aMedian (IQR) or frequency with number/total number (%).
bP-values resulting from mixed linear or logistic regression models and Analysis of Deviance Table (Type II Wald chi-square tests). Nominal variables were tested with
Pearson’s Chi-squared test.
AAD, antiarrhythmic drug; BL, baseline; CI, confidence interval; IQR, interquartile range; HF, heart failure; ITT, intention to treat; MDRD, Modification of Diet in Renal Disease;
MoCA, Montréal Cognitive Assessment; NOAC, non vitamin-K-antagonist oral anticoagulant; VKA, vitamin K antagonist.


















Most patients who were asymptomatic at baseline remained asymp-
tomatic. Only 144/687 (21%) of initially asymptomatic patients became
symptomatic in the first 2 years of follow-up, with no difference be-
tween randomized groups (P = 0.19, Figure 3). In symptomatic patients,
AF symptoms decreased over time with 1104/1832 (60.3%) initially
symptomatic patients becoming asymptomatic during follow-up.
Discussion
Main findings
This prespecified comparison of the effect of early rhythm control
therapy in asymptomatic patients with AF randomized in the EAST-
AFNET 4 trial yielded several new findings:
Figure 2 Aalen–Johansen cumulative-incidence curves for the first primary outcome: (A) for patients with asymptomatic atrial fibrillation at base-
line and (B) for patients with symptomatic atrial fibrillation at baseline. The first primary outcome was a composite of death from cardiovascular
causes, stroke, or hospitalization with worsening of heart failure or acute coronary syndrome. The effect of early rhythm control on this outcome
was almost identical in symptomatic and asymptomatic patients.
............................................. ............................................. .................................................
....................................................................................................................................................................................................................
Table 2 Rhythm control planned at baseline and present at 24 months by EHRA score and randomized












n 395 406 666 692 244 230
Rhythm control at BL
AF ablation 24 (6.1) 1 (0.2) 55 (8.3) 0 (0.0) 23 (9.4) 1 (0.4)
Dronedarone 72 (18.2) 0 (0.0) 88 (13.2) 0 (0.0) 62 (25.4) 1 (0.4)
Amiodarone 82 (20.8) 7 (1.7) 119 (17.9) 12 (1.7) 60 (24.6) 7 (3.0)
Flecainide 127 (32.2) 6 (1.5) 271 (40.7) 10 (1.4) 62 (25.4) 5 (2.2)
Propafenone 35 (8.9) 1 (0.2) 48 (7.2) 1 (0.1) 13 (5.3) 0 (0.0)
Other antiarrhythmic drug 38 (9.6) 1 (0.2) 46 (6.9) 0 (0.0) 18 (7.4) 1 (0.4)
None 17 (4.3) 390 (96.1) 39 (5.9) 669 (96.7) 6 (2.5) 215 (93.5)
Rhythm control at FU24
AF ablation 75 (19.0) 24 (5.9) 124 (18.6) 44 (6.4) 52 (21.3) 19 (8.3)
Dronedarone 23 (5.8) 1 (0.2) 28 (4.2) 2 (0.3) 26 (10.7) 2 (0.9)
Amiodarone 49 (12.4) 11 (2.7) 73 (11.0) 15 (2.2) 34 (13.9) 12 (5.2)
Flecainide 57 (14.4) 5 (1.2) 173 (26.0) 26 (3.8) 34 (13.9) 5 (2.2)
Propafenone 19 (4.8) 3 (0.7) 26 (3.9) 9 (1.3) 7 (2.9) 4 (1.7)
Other antiarrhythmic drug 19 (4.8) 2 (0.5) 17 (2.6) 2 (0.3) 7 (2.9) 1 (0.4)
None 153 (38.7) 360 (88.7) 225 (33.8) 594 (85.8) 84 (34.4) 187 (81.3)
AF, atrial fibrillation; FU24, 24 months follow-up.








































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































..(1) Asymptomatic and symptomatic patients share many clinical charac-
teristics, including similar CHA2DS2VASc scores with slight differen-
ces in the type of comorbidities and more first diagnosed or
persistent forms of AF in asymptomatic patients.
(2) Anticoagulation and treatment of concomitant cardiovascular con-
ditions was not different between asymptomatic and symptomatic
patients.
(3) Asymptomatic patients randomized in EAST-AFNET 4 received an
almost identical early rhythm control therapy compared to symp-
tomatic patients, including AF ablation in approximately a quarter of
patients still in follow-up at 2 years after randomization.
(4) The effect of rhythm control therapy on cardiovascular complica-
tions in asymptomatic patients with AF is not different to the effect
in symptomatic patients and is not affected by symptom severity.
Our findings support systematic, early initiation of rhythm control
therapy in all patients with AF and concomitant cardiovascular condi-
tions independent of their AF-related symptoms (Graphical Abstract).
Current treatment guidelines recommend rhythm control therapy
in symptomatic patients with AF only,1,11 excluding most asymptom-
atic patients from this therapy.7 These recommendations are based
on earlier ‘rate vs. rhythm’ trials showing no effect of rhythm control
therapy in cardiovascular outcomes,12–14 including a neutral outcome
in patients with recently diagnosed AF randomized to rhythm control
therapy in AFFIRM.15 Later, the ATHENA trial randomized asymp-
tomatic and symptomatic patients with AF to treatment with drone-
darone or placebo and found a reduction in a composite of death and
cardiovascular hospitalization, providing a first signal that rhythm con-
trol therapy could convey clinical benefit in patients with AF.9 This
signal was also detected in the CASTLE-AF trial comparing AF abla-
tion to medical therapy in patients with AF and severe heart failure.16
Both trials mainly enrolled symptomatic patients and, unlike AFFIRM,
enrolled patients on continued anticoagulation. On the other hand,
recent data demonstrate the safety of modern rhythm control ther-
apy, including catheter ablation.17–21 However, these results were
obtained in symptomatic patients with a current indication for
rhythm control therapy. The main findings of ATHENA,9 CASTLE-
AF,16 and EAST-AFNET 48 suggest a potential clinical benefit of early
rhythm control therapy, providing a sound rationale to use rhythm
control therapy in asymptomatic patients with AF. The present ana-
lysis demonstrates that early and systematic initiation of rhythm con-
trol therapy in asymptomatic patients with AF enrolled in a variety of
clinical settings conveys the same clinical benefit as in symptomatic
patients. Further details of the therapies used to deliver the early
rhythm control treatment strategy, which included AF ablation in
25% of patients randomized to early rhythm control and still in
............................... ................................. .................................
....................................................................................................................................................................................................................
Table 4 Safety outcomes for EHRA score
















n 395 406 666 692 244 230
Primary composite safety outcome 79 (20.0) 63 (15.5) 99 (14.9) 105 (15.2) 44 (18.0) 43 (18.7)
Stroke 19 (4.8) 25 (6.2) 14 (2.1) 22 (3.2) 6 (2.5) 12 (5.2)
Death 45 (11.4) 40 (9.9) 59 (8.9) 84 (12.1) 29 (11.9) 30 (13.0)
Serious adverse event of special interest related
to rhythm control therapy
22 (5.6) 4 (1.0) 31 (4.7) 8 (1.2) 12 (4.9) 5 (2.2)
Serious adverse event related to antiarrhythmic drug therapy
Nonfatal cardiac arrest 0 (0.0) 0 (0.0) 1 (0.2) 0 (0.0) 0 (0.0) 1 (0.4)
Drug induced bradycardia 0 (0.0) 0 (0.0) 7 (1.1) 3 (0.4) 5 (2.0) 1 (0.4)
Torsade de pointes tachycardia 0 (0.0) 0 (0.0) 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0)
Drug toxicity of AF-related drug therapy 3 (0.8) 2 (0.5) 5 (0.8) 0 (0.0) 2 (0.8) 1 (0.4)
Atrioventricular block 1 (0.3) 0 (0.0) 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0)
Serious adverse event related to AF ablation
Pericardial tamponade 0 (0.0) 0 (0.0) 2 (0.3) 0 (0.0) 1 (0.4) 0 (0.0)
Blood pressure related event 1 (0.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
Syncope 1 (0.3) 0 (0.0) 2 (0.3) 0 (0.0) 1 (0.4) 1 (0.4)
Other serious adverse event of special interest related to rhythm control therapy
Other event 1 (0.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (0.9)
Other cardiovascular event 4 (1.0) 0 (0.0) 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0)
Major bleeding related to AF ablation 3 (0.8) 0 (0.0) 3 (0.5) 0 (0.0) 0 (0.0) 0 (0.0)
Hospitalization for AF 4 (1.0) 0 (0.0) 6 (0.9) 3 (0.4) 1 (0.4) 0 (0.0)
Nonmajor bleeding related to AF ablation 0 (0.0) 1 (0.2) 1 (0.2) 1 (0.1) 0 (0.0) 0 (0.0)
Hospitalization for worsening of HF with decompensated HF 2 (0.5) 0 (0.0) 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0)
Implantation of a pacemaker, defibrillator or other 3 (0.8) 1 (0.2) 1 (0.2) 2 (0.3) 3 (1.2) 1 (0.4)
AF, atrial fibrillation.



















































.follow-up at two years, and antiarrhythmic drugs in 75% of patients,
have been published.22
Clinical characteristics of asymptomatic
patients with AF
Asymptomatic patients enrolled into EAST-AFNET 4 were older
than symptomatic patients, had a similar CHA2DS2VASc score, but
with slight differences in risk factor profiles, and were less frequently
in paroxysmal AF (Table 1). This is different from the asymptomatic
patients enrolled into AFFIRM and RACE who tended to be younger
and had less comorbidities than symptomatic patients in those tri-
als.23,24 The clinical characteristics of the asymptomatic AF popula-
tion in EAST-AFNET 4 replicate features of asymptomatic patients in
contemporary European and American general AF registries.4–7
These similarities suggest that the findings of this subanalysis are ap-
plicable to general patients with asymptomatic AF.
Asymptomatic patients had fewer attempts of rhythm control
therapy at the time of enrolment into EAST-AFNET 4, which is in line
with the current guideline recommendations restricting rhythm con-
trol therapy to the improvement of symptoms in symptomatic
patients with AF.1,11 This observation underscores the potential im-
pact of the present analysis demonstrating a relevant reduction in the
composite of cardiovascular death, stroke, or hospitalization for
heart failure or acute coronary syndrome in asymptomatic patients
with AF. Almost all patients enrolled into EAST-AFNET 4 had clinic-
ally diagnosed AF, which could include AF detected during routine
medical visits, e.g. during vaccination. These results call for further
research into the value of rhythm control therapy in patients under-
going active screening for AF.
Symptoms and quality of life in
asymptomatic atrial fibrillation
The positive effect of early rhythm control on the primary outcome
was not associated with improved quality of life in EAST-AFNET 4,
neither in symptomatic nor in asymptomatic patients. While details
of this observation remain to be analyzed, a plausible explanation is
the comparator (‘usual care’) in EAST-AFNET 4: Patients randomized
to usual care received rhythm control therapy to improve symptoms
on optimal rate control.10 About 15% of patients randomized to
usual care received rhythm control therapy. This symptom-directed
and delayed rhythm control therapy in patients randomized to usual
care can explain the high proportion of patients with well-controlled
symptoms in both randomized groups in the trial. It is possible that a
higher use of AF ablation, used in 25% of asymptomatic patients with
AF who were randomized to early therapy and still in follow-up at
two years in this analysis, and in a similar proportion in the overall
trial, could have improved quality of life even further.19,25–27 This
should be studied in future trials.
Most patients who were included in EAST-AFNET 4 without AF-
related symptoms remained asymptomatic. Only 21.7% of initially
asymptomatic patients became symptomatic during follow-up, with
no difference between treatment groups. The results of this analysis
demonstrate that systematic, early rhythm control therapy reduces
cardiovascular outcomes in patients with recently diagnosed AF irre-
spective of AF-related symptoms. These facts invite a fundamental
Figure 3 Change in atrial fibrillation symptoms between discharge from baseline and 24 months follow-up. There were no differences in symptom
status at 24 months between randomized groups, irrespective of the presence of baseline symptoms (P = 0.1161). Symptoms improved without in-
ter-group difference, illustrating the good adherence to protocol in patients randomized to usual care, which included symptom-directed rhythm
control therapy to improve atrial fibrillation-related symptoms.































































































rethink regarding the treatment of AF. In our view, these findings call
for the inclusion of rhythm control therapy early and systematically in
asymptomatic patients with AF and concomitant cardiovascular
conditions.
Limitations
Although the EAST-AFNET 4 trial was a randomized, multicentre
controlled trial, it was not powered for a primary analysis of asymp-
tomatic patients. The directionality and the magnitude of the effect
on the primary outcome and of its components were comparable to
the effect in symptomatic patients and in the overall trial population.
The 95% confidence interval of the hazard ratio for the primary out-
come (0.76 [0.57, 1.03]) included 1, as could be expected due to the
lower number of patients in this subgroup. Symptoms can be difficult
to assess, and asymptomatic patients occasionally report improved
symptoms after restoration of sinus rhythm. Furthermore, symptom
assessment in this subanalysis was limited to the EHRA score, a vali-
dated26 but general instrument capturing symptoms related to AF.
Conclusions
These results call for a shared decision process discussing the benefits
of rhythm control therapy in all patients with recently diagnosed AF
and concomitant cardiovascular conditions regardless of their AF-
related symptoms (EAST-AFNET 4 ISRCTN number,
ISRCTN04708680; ClinicalTrials.gov number, NCT01288352;
EudraCT number, 2010-021258-20).
Supplementary material
Supplementary material is available at European Heart Journal online.
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